Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Progress in Hyaluronan-Based Nanoencapsulation Systems for Smart Drug Release and Medical Applications

Valachová K., Hassan ME., Tamer TM., Šoltés L.

Narrative Review on Osteoarthritis, Chronic Wound, Chronic Inflammation, Autoimmune Research, published in Molecules (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Molecules (2025)
Reported sample size
—
Source database
Europe PMC
PMID
41097302
PMCID
PMC12525940
DOI
10.3390/molecules30193883
Citations
3

Abstract (original English)

Hyaluronan (HA), a high-molecular-weight polysaccharide naturally found in vertebrate tissues such as skin, joints, and the vitreous body, plays a critical role in various biological processes. Its functionality is highly dependent on molecular weight, with high-molecular-weight HA exhibiting anti-inflammatory and immunosuppressive effects, while low-molecular-weight HA promotes inflammation, immunostimulation, and angiogenesis. Due to its biocompatibility, biodegradability, and tunable properties, HA has gained increasing attention in biomedical applications. This review summarizes recent advances in the encapsulation of HA with other polymers and therapeutic agents in nanosystems, particularly hydrogels and nanoparticles. HA-based formulations demonstrate improved therapeutic outcomes, including drug release sustained up to 7 days, wound closure rates exceeding 90% in animal models, particle size in the range of 50-300 nm, and enhanced bioavailability of encapsulated drugs by 2-3 fold compared with free drugs. Such properties have shown promise in enhancing therapeutic efficacy and targeted drug delivery in the treatment of skin wound healing, diabetes, osteoarthritis, rheumatoid arthritis, and ophthalmic diseases. The review emphasizes how HA's modifications and composite systems optimize drug release profiles and biological interactions, thereby contributing to the developm

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsHumansHyaluronic AcidHydrogelsDrug CarriersDrug Delivery SystemsDrug CompoundingWound HealingNanoparticlesDrug Liberation

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research